US-based stents developer Svelte Medical Systems has started patient enrolment in the OPTIMIZE clinical study of its drug-eluting stent (DES) Integrated Delivery System (IDS) and Rapid Exchange (RX) platforms.

Svelte IDS is a fixed-wire DES designed to downsize catheters to allow transradial intervention (TRI) and direct stenting, eliminating steps, time, and cost associated with coronary stent procedures.

Both the CE-Marked IDS and RX systems employ low-profile, conformable stents, and new bioresorbable drug carrier eluting sirolimus.

The randomised, controlled OPTIMIZE study will evaluate the safety and effectiveness of the DES platforms, and the results are expected to support their approval for atherosclerotic coronary lesion treatment in the US and Japan.

While the study is set to recruit around 2,000 subjects at up to 125 centres in the US, Japan, and Europe, the first patient was enrolled at the Christ Hospital, Lindner Research Center in Ohio, US.

“OPTIMIZE will be a landmark study for interventional cardiology.”

OPTIMIZE study principal investigator Dean Kereiakes said: “OPTIMIZE will be a landmark study for interventional cardiology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Not only is it evaluating an entirely new approach to coronary stent delivery utilising novel concepts and next-generation technologies, OPTIMIZE is the first trial to evaluate, in a prospective, randomised fashion, direct stenting as well as the potential health economic impact derived by streamlining PCI.”

The study is based on prior positive data reported from the DIRECT I and DIRECT II studies that assessed the Svelte IDS’ feasibility, safety, and efficacy, respectively.

Svelte Medical Systems president and CEO Jack Darby said: “Our highly differentiated platforms improve procedural efficiency and reduce cost while enhancing patient outcomes and comfort, delivering value to all constituents involved in coronary stenting – patients, physicians, providers and payers.”